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Abstract 
Background 
Inflammatory bowel disease (IBD) is a chronic condition with an unpredictable disease 
course. Rates of anxiety and depression among IBD patients in relapse (active disease 
symptoms) as well as in remission are higher than in the general population. Previous studies 
suggest that the prolonged effect of pain, anxiety, distress and depression have a detrimental 
effect on patients’quality of life (QoL). Poor QoL in itself is associated with further symptom 
relapse. Mindfulness based cognitive therapy (MBCT) is a psychological group intervention 
that has the potential to improve QoL. When used in other chronic conditions, it 
demonstrated reduced negative effect from pain and psychological factors at completion of an 
8-week MBCT course. The effect of MBCT has never been researched in IBD. The aim of 
this study is to obtain the information required to design a full scale randomised controlled 
trial (RCT) that will examine the effectiveness of MBCT in improving quality of life for IBD 
patients. 
Methods/Design 
This is an exploratory RCT with embedded process evaluation. Forty IBD patients will be 
recruited from NHS outpatient gastroenterology clinics and will be randomised to either a 
MBCT (intervention) group or to a wait-list (control) group. All participants will undergo 16 
h of structured group training over an 8-week period, with the control group starting 6 months 
later than the intervention group. Primary outcomes are recruitment, completion/retention 
rates and adherence and adaptation to the MBCT manual for IBD patients. The secondary 
outcome is to assess the feasibility of collecting reliable and valid data on proposed outcome 
measures such as quality of life, anxiety, depression, disease activity and mindful awareness. 
The process evaluation will use a survey and focus groups to assess the acceptability of the 
intervention and trial procedures for IBD patients. 
Discussion 
The outcomes of this study will help define the barriers, uptake and perceived benefits of 
MBCT program for IBD patients. This information will enable the design of a full-scale 
study assessing the effect of MBCT on quality of life for IBD patients. 
Trial registration 
Current Controlled Trials: ISRCTN27934462 
Keywords 
Mindfulness-based cognitive therapy, Inflammatory bowel disease, Crohn’s disease, 
Ulcerative colitis, Quality of life, Pilot randomised controlled trial 
Background 
Inflammatory bowel disease (IBD) is a group of relapsing chronic gastrointestinal conditions 
characterised by inflammation of the gut [1,2]. The condition affects the normal function of 
the gastrointestinal system, resulting in symptoms such as bloody diarrhoea, vomiting, severe 
pain and malnutrition [3,4]. It affects approximately 250,000 people in the UK and 28 million 
worldwide with its incidence rising [5,6]. The two main types are Crohn’s disease (CD) and 
ulcerative colitis (UC). While there is a concern about the increased risk of colorectal cancer 
in IBD patients [7], the main burden for patients is the relapsing course of the disease and its 
detrimental impact on psychosocial functioning and quality of life [8]. 
Anxiety, depression and quality of life in IBD 
Anxiety and depression rates among IBD patients are higher than in the general population 
even in remission (when symptoms are settled) [9,10]. Previous studies have suggested that 
the prolonged effect of pain, anxiety, distress and depression have detrimental effects on 
quality of life (QoL) [11]. Poor QoL is further associated with symptoms relapse and 
additional clinical difficulties such as tissue inflammation [12,13]. Anxiety, depression and 
relapse thus links together in a self-perpetuating cycle with pernicious implications for those 
affected. 
Use of medication for management of anxiety, depression and pain and its 
limitations 
Evidence suggests that the use of antidepressants can have a positive effect on QoL and 
symptom management for IBD patients by reducing anxiety and depression [14-16]. This is 
encouraging. However, some patients using antidepressants have reported unpleasant side 
effects while others have reported that the antidepressants have no effect on their low mood 
or anxiety [17-19]. 
The use of painkillers for pain management also has its limitations. There are subgroups of 
IBD patients who irrespective of using anti-inflammatory and pain medication continue to 
suffer severe discomfort, again with a knock-on effect and making symptom exacerbation 
more likely [20]. 
In addition, poor medication compliance is frequently reported among IBD patients, with up 
to 40% of patients regularly omitting their prescribed medications [21,22]. Pharmacology is 
thus very limited. The search for alternative evidence-based approaches is a pressing concern. 
Mindfulness based cognitive therapy 
Mindfulness based cognitive therapy (MBCT) is a non-pharmacological psychological group 
program designed by Segal et al. [23]. The MBCT program is largely based on the 
mindfulness-based stress reduction (MBSR) program developed by Jon Kabat- Zinn for 
coping with stress and chronic illness [24]. Both programs involve teaching individuals 
various stress management, relaxation, self-care and self-help techniques in a systematic way 
over an 8-week period. In both, the core skill taught is mindfulness, which uses meditation 
practice to increase attention and awareness [25]. The working definition of mindfulness in 
the program is: ‘The awareness that emerges through paying attention on purpose, in the 
present moment, and nonjudgmentally to the unfolding of experience moment by moment’ 
[26]. The main difference to the MBSR program is that MBCT has combined cognitive 
therapy exercises with the mindfulness skill. This combination is believed to further enable 
patients to increase their awareness and facilitate early recognition of any recurring unhelpful 
thinking patterns often associated with depressive symptoms and anxiety [23]. Hence, the 
National Institute for Health and Care Excellence guidelines makes a recommendation for the 
use of MBCT program as a psychological intervention in the ‘clinical management of 
persistent sub threshold depressive symptoms or mild, moderate or severe depression in 
adults (including people with a chronic physical health problem)’ [27]. 
Although the exact mechanism of how mindfulness-based interventions work is not yet fully 
understood, the evidence so far suggests that at program completion, participants would 
experience reduced negative effects from pain, distress, anxiety and depressive symptoms. 
For example, a systematic review and a meta-analysis of the effectiveness of mindfulness-
based interventions on anxiety, depression and psychological distress in patients with chronic 
pain conditions [28] and chronic medical conditions [29] such as fibromyalgia, cardiac and 
cancer patients, have shown positive effect on anxiety, depression and psychological distress. 
An observational study examining the relationship between mindfulness, QoL, depression 
and anxiety in patients with ulcerative colitis found a positive association between increasing 
mindfulness and reducing depression and anxiety [30]. However, MBCT and its effect on 
QoL has never been researched in a RCT with both Crohn’s and ulcerative colitis patients. 
Thus, the MBCT program may be the therapy that can provide a relief from the negative 
effects of a lifelong management of the disease for IBD patients. 
Hypothesis 
The hypothesis is that MBCT will improve QoL scores for IBD patients as well as improve 
anxiety and depressive symptom scores. This hypothesis is based on previous studies of using 
mindfulness based programs in other chronic condition populations. Hence, the proposed 
pilot study is the first step towards testing the hypothesis in a definitive RCT and gathering 
the necessary knowledge to close the existing evidence gap regarding the usefulness of 
MBCT for IBD patients. 
Aims and objectives 
The overall aim of this study is to pilot the MBCT program with IBD patients in a RCT and 
examine the feasibility of running a large RCT testing the above hypothesis. 
The specific objectives of the pilot are: 
1. To determine the feasibility of conducting a large-scale RCT of group MBCT for 
improvement of IBD QoL. 
2. To adapt the intervention manual devised by Segal et al. [31], outlining how to carry out 
an MBCT program for IBD patients. 
3. To use data arising from differences between MBCT and control arm to inform a power 
calculation for sample size of a definitive RCT. 
4. Estimate trial eligibility, recruitment (percentage of IBD patients who consent to the trial) 
and completion/retention rates (percentage of participants completing the trial). 
5. To embed a process evaluation within the pilot trial to assess the acceptability of the 
intervention and trial procedures for IBD patients, such as: 
a. Acceptability of recruitment, randomisation and consent procedure 
b. Acceptability and feasibility of collecting reliable and valid data on primary and 
secondary outcomes (including follow-up at 6 months) 
c. Fidelity of intervention. 
d. Acceptability of length of intervention 
e. Appropriateness/suitability of the intervention used 
f. Barriers to attendance 
g. Expectations about intervention 
h. Perceived impact on QoL 
 
Methods and design 
Design 
This exploratory trial is designed in two phases. Phase 1 is a two-arm pilot RCT (MBCT 
treatment vs. wait-list control group) with three assessments (baseline, post treatment and 6 
months). Phase 1 will assess eligibility, uptake, drop-out rates and sample size calculation as 
well as adaptation and adherence to MBCT manual. This design is consistent with similar 
studies where a non-pharmacological intervention is investigated in IBD population [32-38]. 
Phase 2 is a process evaluation assessing the feasibility and acceptability of the intervention, 
primary and secondary outcomes and trial procedures as well as barriers to attendance and 
perceived benefits to patients. This design is in line with the Medical Research Council 
(MRC) framework for the development and evaluation of complex interventions to ensure 
that both the intervention and trial procedures are optimised and can be incorporated into 
routine clinical practice [39]. 
Setting and recruitment 
The study will take place across two health board areas in the north of Scotland, an area 
comprising of approximately 800,000 people living across a large geographical area 
including urban and remote rural locations. Recruitment will focus on gastroenterology 
outpatient clinics. 
Phase 1 - Pilot RCT 
Participant selection 
Less than one-third of RCTs recruit to proposed number [40]. Assessing recruitment is a key 
component of this study. Ensuring an effective recruitment strategy is thus important. 
Accordingly, the recruitment strategy devised in this study draws on best evidence [41] 
tailored to the specific requirements of people with IBD. Specific aspects of the recruitment 
strategy were developed in collaboration with all parties involved in the care of IBD patients, 
namely specialist IBD nurse, gastroenterology clinicians and research nurses. 
Clinical staff at participating gastroenterology outpatient clinics will identify people who 
meet the study’s inclusion criteria. They will approach consecutive patients in clinics or by 
sending an invitation letter with study information and research team contact details. 
Interested participants will then contact the researcher by telephone or email to register 
interest. A screening visit with the researcher will then be arranged. Informed written consent 
will be obtained at the first visit by a member of the research team. 
Inclusion criteria 
1. Be able to verbally communicate and write in English (English does not have to be their 
first language). 
2. Able to give informed consent. 
3. Age of 18 years or over (no upper limit). 
4. Confirmed diagnosis of Crohn’s disease or ulcerative colitis (by clinician). 
5. Ability to do light exercise (for example, to lift arms above the head or bend knees) 
because part of the practices in the program require this movement. 
6. Able to commit to attend the eight sessions (participants should consider their personal 
circumstances to assess if this is practical and feasible for them). 
7. To be able to commit to do home practice of up to 45 minutes daily over the 8 weeks of 
the study (this is a core component of the program). 
8. No change of antidepressants (dose or type) within the last 3 months. Any change of 
antidepressants within the last 3 months might interfere with the program. 
9. Participants will have to be in remission of symptoms. 
Exclusion criteria 
Anyone not meeting the above criteria by definition will be excluded from the study. In 
addition, the following exclusion criteria will apply: 
1. Major psychiatric illness. The treatment for a major psychiatric illness may interfere with 
the program. 
2. Active alcohol or drug dependency. Any alcohol or drug dependency may interfere with 
the program. 
3. Scheduled for major surgery in the next 3 months. Any scheduled surgery within the next 
3 months will interfere with the program schedule. 
4. Participation in a pharmacological study or psychological intervention study within the last 
6 months or intention to participate in a pharmacological study during the duration of this 
study. Both will interfere with the program. 
5. Have recently (within the last 3 months) been prescribed antidepressants. Any change of 
antidepressant in the last 3 months may interfere with the program. 
6. With exacerbated symptoms (acute phase). Having exacerbated symptoms will make it 
very difficult for participants to attend the two hourly sessions or to commit to the home 
practice. This could cause extra unwanted stress for the patient. 
Randomisation 
Randomisation will be performed using a dedicated software solution after participants have 
given written consent and baseline data have been collected. Group allocation will be to 
‘MBCT group’ or ‘wait-list control group’ in a 1:1 ratio. To ensure similarity between the 
groups, randomisation will take account of gender and type of disease. The randomisation 
will be carried out by an independent statistician. 
Minimising bias 
Participants will self-complete all the questionnaires. Data entry will be done by the lead 
researcher and independently checked by a second person. Data analysis will be done by two 
researchers independently and differences will be rectified by a third person. 
MBCT intervention 
The MBCT program used in this study will follow the manual developed by Segal et al. [31]. 
In brief, the manual proposes the following format for the eight group sessions: 
• Welcome and introduction to the session theme 
• A short opening meditation 
• A discussion of at-home practice 
• An introduction and practice of new exercises 
• A group reflection/discussion 
• A review of the next weeks’ at-home practice 
• A closing sitting meditation 
A sample list of activities for session 1 is presented below. The manual also suggests for an 
additional full day of mindful practice to take place between weeks 6 and 7 (usually on a 
weekend). In the full day of practice participants will go through all the learned mediations 
one after another in silence, with the group reflection and discussion taking place at the end 
of the practice day. An example schedule for a day of mindful practice is presented below. 
Due to resource constraint, in this study, the full day of practice will be offered to participants 
after they have completed the 8-week course. 
A sample list of activities for session 1 
Theme: Awareness and automatic pilot 
1. Establish the orientation of the class 
2. Set ground rules regarding confidentiality and privacy 
3. Ask participants to pair up and introduce themselves to each other than to the group as a 
whole, giving their first names and if they wish, saying what they hope to get out of the 
program 
4. The raisin exercise 
5. Feedback and discussion of the raisin exercise 
6. Body scan practice-starting with short breath focus 
7. Feedback and discussion of body scan 
8. Home practice assignment: 
• Body scan for 6 out of 7 days 
• Mindfulness of a routine activity 
• Distribute audio files: cd’s for those that not have email and session 1 participant hand-
outs. 
 
9. Discuss in pairs: 
• Timing for home practice 
• What obstacles may arise 
• How to deal with them 
 
10. End the class with a short 2–3 minute focus on the breath. 
Example schedule for a day of mindful practice [35]. 
9.45-10.00 Arrival 
10.00-10.05 Sit in silence 
10.05-10.20 Welcome, introduction, ground rules 
10.20-10.50 Siting meditation: Breath, body, sounds, thoughts and choiceless awareness 
10.50-11.30 Mindful stretching 
11.30-12.00 Body scan 
12.00-12.05 Instruction for lunchtime: bringing focus on awareness of eating, tasting, chewing, 
swallowing, slowing down 
12.05-13.05 Lunch followed by mindful walk 
13.05-13.20 Sitting meditation 
13.20-13.50 Walking meditation 
13.50-14.20 Mountain meditation 
14.20-14.40 Mindful stretching 
14.40-15.00 Silent sit or extended breathing space 
15.00-15.30 Feeding back experience of day in pairs 
15.50-16.30 Large group discussion and close 
The program will be delivered by two experienced MBCT practitioners that have been 
briefed on the key concerns and difficulties that IBD patients experience as well as the nature 
of the disease. An experienced practitioner will have completed an 8-week MBCT course and 
maintained a personal practice for at least 1 year. In addition they will have facilitated at least 
one 8-week MBCT program. 
Participants will be encouraged to do daily home practice for the duration of the program and 
keep a home practice diary. Participants will be provided with guided practice CDs and hand-
outs with a written summary for each session and instruction for home practice. Each weekly 
session will be approximately 120 minutes and will be audio recorded. 
Wait-list control 
The control group will continue to receive their standard care and in addition will receive a 
leaflet entitled ‘Staying well with IBD’. The leaflet is readily available to download from the 
Crohn’s and Colitis UK website, but participants in the study will receive a printed copy [42]. 
After 6 months follow-up data are collected; the wait-list group will have an opportunity to 
attend a MBCT program if they wish. 
Data collection 
A screening and recruitment log will be completed by a researcher to document all patients 
considered for the study and subsequently included or excluded at each stage of the 
recruitment process with reasons given. This log will include information such as date when 
information was given about the study, and date of recruitment and randomisation. The data 
will inform the estimate for recruitment rates for a full trial and address aims 1 and 4. A full 
consort diagram of subject flow is presented in Figure 1. 
Figure 1 Consort diagram describing flow of patients through study. 
At baseline, demographic information including age, gender, education, income and marital 
status will be recorded, to allow the success of randomisation to be assessed [43]. 
The MBCT practitioners will complete an attendance log to document the number of practice 
sessions attended by each participant. This log will inform the estimated attrition rates for a 
full trial and will address aim 3. 
Semi-structured interviews with the practitioners delivering the MBCT intervention will be 
conducted to find out if any changes to the manual should be done to accommodate the needs 
of this patient group. This will address aim 2. 
Outcomes and assessments 
The outcomes for this study are consistent with relevant published studies assessing the use 
of mindfulness-based program in populations with chronic health problems [44] as well as 
with studies investigating the effects of non-pharmacological programs on QoL in IBD 
patients [35,36,45]. They include assessment of disease specific QoL, mood, mindful 
awareness, disease activity and demographics. All assessment tools used in the trial are 
validated and reliable. All outcomes will be assessed at baseline, post treatment and 6 
months. 
Proposed primary outcome 
Quality of life 
All participants will be required to complete the disease specific IBD quality of life 
(IBDQoL) questionnaire consisting of 32 questions. The questionnaire has four domains, 
including bowel symptoms, systemic symptoms, emotional factors and social factors. Within 
the questionnaire, participants will rate their symptom experience over the previous 2 weeks. 
Low scores indicate more severe disease activity and/or higher emotional and social 
dysfunction. A relatively good correlation between the IBDQoL and a widely used measure 
of disease activity, the Crohn’s Disease Activity Index is reported (r = −0.67; P <0.001) 
[46,47]. 
Proposed secondary outcomes 
Anxiety 
Anxiety will be measured by the State and Trait Anxiety Inventory (STAI) Y1 and Y2 form, 
consisting of 40 questions on a self-report basis. The inventory measures two types of 
anxiety: anxiety related to an event and anxiety level as a personal characteristic. Higher 
scores are positively correlated with higher levels of anxiety [48]. This tool is widely used to 
measure anxiety and regarded as highly reliable [13]. 
Depression 
Low mood and depression symptoms will be measured with the Beck’s depression inventory 
(BDI-II), consisting of 21 group of statements referring to the last 2 weeks. Each answer is 
being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive 
symptoms. Previous studies indicate the internal consistency of the BDI-II is high [49,50]. 
Disease activity 
Disease activity will be measured with the eight-item questionnaire Crohn’s Disease Activity 
Index (CDAI) for Crohn’s patients [51,52] and six-item questionnaire Simple Clinical Colitis 
Activity Index (SCCAI) for ulcerative colitis patients [53]. Both tools are widely used to 
measure disease activity with IBD patients. 
Mindful attention 
Mindful attention will be measured with the 15-item scale Mindful Attention Awareness 
Scale (MAAS). This scale consists of collection of statements about everyday experiences 
graded by participants, using a scale of 1 to 6 which indicates how often each experience 
occurs. Higher scores reflect higher levels of dispositional mindfulness. The validation of this 
tool has been examined in a series of studies indicating strong psychometric properties and 
validity [54,55]. 
Phase 2 - Process evaluation 
To address aim 5 and examine the implementation and receipt of the intervention and trial 
procedures, a detailed process evaluation will be undertaken. This evaluation process will 
assess the acceptability of recruitment, randomisation and consent procedure for patients, 
acceptability and feasibility of collecting reliable and valid data on primary and secondary 
outcomes, fidelity of protocol, acceptability of length of intervention for patients, 
appropriateness/suitability of the intervention used, barriers to attendance, expectations about 
intervention and perceived impact on QoL. 
Observations of MBCT training sessions will be undertaken by audio recording of all 
sessions to assess if specific components of the protocol are delivered and to use the 
qualitative data to assess the appropriateness of the intervention used. These data will address 
aim 5c. 
All participants will be asked to self-complete a postal survey asking their views on research 
procedures such as consent and randomisation procedures and reliability of questionnaires. 
The MBCT group will answer further questions on expectations, acceptability, 
appropriateness and perceived impact of the intervention as well as the length of the program. 
These data will address aims 5a, 5e, 5f, 5 g and 5 h. 
A post-intervention focus group will be facilitated to further explore the participants’ views 
and experiences of the MBCT program and trial procedures, using the themes from the 
survey. The focus groups will be audio recorded. A list of topic guides for the focus group is 
presented below. 
List of topic guides for the focus groups 
Expectations 
1. Did you have any expectations regarding the self-help program? 
2. If yes, what were they? 
3. Were your expectations met/ unmet in any way? And How? 
Length and difficulty of program 
4. Was the length of eight weeks for the program acceptable? 
5. Did you find the program difficult to follow? 
6. Please tell us which specific parts of the program you found difficult to follow. 
Potential benefits 
7. Do you think this program has brought any benefit to you? 
8. Please tell us how you think the program benefited you. 
9. Do you think you will continue to use some of the techniques you learned in the program? 
Recruitment and randomisation 
10. Do you think the process of recruitment was acceptable? 
11. Do you think the patient information sheet was easy to understand? 
12. Any suggestions to make it clearer to understand 
13. Did you feel comfortable with the process of consent and randomisation? 
Questionnaires 
14. Was filling the questionnaires at the start and at the end of the eight weeks too much of a 
burden? 
15. Can you please tell us what difficulties you came across with the questionnaires and 
perhaps any suggestions of how to overcome those difficulties 
Barriers to attending 
16. Were there any barriers to attending the program? 
17. Can you please tell us what you think were barriers to attendance? 
What did you enjoy? 
18. Did you enjoy the program? 
19. Which parts did you most enjoy? 
Availability of MBCT program 
20. Do you think this program should be made available to IBD patients through NHS? 
Ethical and research and development approval 
A favourable ethical opinion was obtained from NRES Committee for North of Scotland on 
8th April 2013 (REC ref 13/NF/0018). NHS Highland and NHS Grampian R&D 
Management Approval was obtained on 9 April 2013 and 14 September 2013, respectively. 
Sample size 
The nature of this study is a pilot RCT. Thus, a formal sample size calculation was not 
performed. The determined sample size of n = 40 was calculated based on the estimated 
number of participants expected to complete the 8-week program. 
This number was achieved by the following calculation. Recommendation for pilot sample 
size calculation is 30 [56,57]. Literature suggest that attrition rate of approximately 25% is to 
be reasonably expected in mindfulness intervention studies [58]. A sample size of 40 with a 
25% attrition rate will give an estimated sample of 30 subjects completing the 8-week 
program. 
The approximate number of IBD patients is 600 in NHS Highland and 1,741 at NHS 
Grampian. With estimated recruitment rates of IBD interventional studies ranging between 
10% and 20% (234 to 468 between the two sides), a sample size of 40 is reasonably 
achievable. 
Analysis 
Audio-recorded focus groups and interviews with practitioners will be transcribed verbatim. 
Transcripts will be analysed thematically using the framework analysis approach [59] which 
is a rigorous method that allows themes to be identified (and organised) within the groups or 
between the groups. Hence, notable differences in experiences and perceptions can be 
identified. 
From quantitative data we will generate the following: estimates of eligibility, recruitment 
and retention rates, speed of recruitment, and completion rates of study assessment tools 
(objectives 1 and 4); Descriptive presentations of the proposed primary and secondary 
outcomes will be made to inform a sample size calculation for a large-scale trial and 
decisions as to whether their inclusion would be informative in a future trial (objective 3). 
Discussion 
There is increasing evidence that mindfulness-based interventions can provide benefits to 
people with chronic ill health in terms of improving QoL and reducing anxiety and depressive 
symptoms. However, the use of these interventions in patients with both CD and UC is not 
researched. This paper outlines a protocol for a pilot RCT with embedded process evaluation 
that aims to provide data on eligibility, uptake and retention rates, barriers to recruitment and 
attendance and perceived benefit to IBD patients. This information is required to design a 
full-scale RCT assessing the effectiveness of MBCT on QoL for IBD patients. 
This study is the first RCT to examine the use of MBCT in patients with IBD. The study 
design is a multicentred RCT and uses robust methods to evaluate feasibility and 
acceptability of the intervention in patients with IBD. The 6-month follow-up data will give 
an indication as to how long (if any) benefit from the intervention would last. The type of 
information that will be collected from the evaluation process will give an insight into 
important questions such as participants’ subjective thoughts and experiences about the 
intervention (expectations, potential benefits, barriers to attending and availability of the 
program through NHS) as well as their feedback on recruitment process and procedures. 
In addition, the results of this project will provide important information on integration of 
mindfulness-based interventions with usual medical care as well as application of MBCT for 
IBD. 
Trial status 
Recruitment commenced in May2013 and is ongoing. 
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